HAE · NYSE · STOCK
Haemonetics (HAE) Stock Analysis
$102.83
52W $47.32 – $109.57
55/100
$4.67B
49.9
0.52
Is HAE Bullish or Bearish?
Mixed.
Innellis AI committee rates Haemonetics (HAE) Watch with a composite score of 55/100
, based on 6 analysts with 50% agreement.
Last updated September 05, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +4.90 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -15.10 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+0.75 across 4 articles, 14d). Value Analyst remains cautious — p/e of 48.5 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- News sentiment is positive (+0.75 across 4 articles, 14d) — News
Bear Case
- P/E of 48.5 is expensive by classic value standards — Value
- Debt-to-equity of 1.54 adds balance-sheet risk to the value case — Value
- EPS declining -37.4% YoY despite any revenue growth — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 77 -- overbought on the larger timeframe too — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of September 05, 2026
Overall Committee Score
55/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 71%
of 192 Healthcare peers
Value Analyst
bearish
37
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− P/E of 48.5 is expensive by classic value standards
Growth Analyst
neutral
44
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ 5 consecutive earnings beats -- consistent execution
− EPS declining -37.4% YoY despite any revenue growth
Technical Analyst
neutral
58
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst
neutral
45
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
− High leverage (debt-to-equity 1.54) amplifies downside in a stress scenario
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
82
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.75 across 4 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3059.07)
Investment Thesis Evolution
Committee score moved marginally from 53.8 to 55.1.
- Bullish support removed: 1 signal(s) disappeared.
- New bullish signals: 1 appeared.
Analyst-level changes:
- News Analyst: score 74->82 (+8); +1 bullish signal(s).
Comparing 2026-09-04 to 2026-09-05 (1 day apart).
Technical Analysis
RSI (14)
55.4
Neutral
MACD Histogram
-0.868
Bearish Momentum
Trend Direction
Uptrend
Weekly: Sideways
Market Structure
Hh Hl
Support
$84.46
Resistance
$141.71
Bollinger %B
0.59
Inside Bands
Price vs Moving Averages
EMA 9
$103.25
Below
EMA 21
$99.21
Above
EMA 50
$89.89
Above
EMA 200
$74.57
Above
Fundamental Analysis
Valuation
46
Growth
56
Profitability
58
Financial Health
77
Cash Flow
70
Valuation
P/E Ratio
49.9×
P/B Ratio
5.57×
PEG Ratio
-1.34
Dividend Yield
0.00%
52W High
$109.57
52W Low
$47.32
Quality & Growth
ROE
1222.0%
ROA
406.1%
Gross Margin
5738.4%
Operating Margin
1817.6%
Revenue Growth YoY
—
Debt / Equity
1.40
AI Fundamental Assessment
P/E ratio of 49.9 (rich relative to a 15-40x range); Price-to-book of 5.6x; PEG ratio of -1.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 12.2%; Return on assets of 4.1%; Net margin of 7.1%; Gross margin of 57.4%; Current ratio of 3.08 (healthy short-term liquidity); Debt-to-equity of 1.40; Free cash flow per share is positive (6.42); Most recent quarter beat estimates by 4.8%; 5 consecutive earnings beats; EPS growth decelerating (-1.5% -> -11.6% QoQ); Average YoY EPS growth of 3.6%; Analyst estimates falling over recent quarters
Get the Full HAE Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →